Patent · US Active

IL4/IL13 binding repeat proteins and uses

US8722618B2 · kind B2 · utility

32Cited by

2References

10Claims

0Family size

Assignee

JANSSEN BIOTECH, INC. · US

Inventors

Steven Jacobs · North Wales, US
Karyn O'Neil · Spring House, US
Michael Baumann · Herrenberg, DE
Gaby Sennhauser · Pfäffikon, CH

Key dates

Filing date	Apr 27, 2012
Grant date	May 13, 2014
Priority date	—
Expiry date	Apr 27, 2032

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

IL4/IL13-binding proteins comprise binding domains, which inhibit IL4/IL13 binding to IL4Ralpaha and common gamma chain complexes (Type 1) and inhibit IL4 binding to IL4Ralpha and IL13Ralpha1 complexes (Type 2), and IL13 binding to IL13Ralpha1 and/or IL13Ralpha2, are useful in the treatment of cancer, inflammatory, and other pathological conditions, such as allergic or fibrotic conditions, especially pulmonary conditions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.